CRISPR Therapeutics CRSP reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.27 per share. In the year-ago period, the company ...

Q3 Revenue declined 11% YoY to $390.35M, below the $411.62M estimate. North America sales fell 10%, while adjusted EPS of $0.07 missed the $0.13 forecast. Don’t miss this list of 10 overlooked ...

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9% ...

Shares of Pool Corp. POOL slid 3.56% to $295.34 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.77% to 5,606.91 and Dow ...

Terra Chips Maker Hain Celestial Seeks Strategic Options For Business, Announces CEO Transition, Stock Tanks Shivani Kumaresan Wed, May 7, 2025, 1:22 PM 2 min read ...

But if were to go by ICICI Securities, the stock stares at further downside potential. The domestic brokerage has suggested a 'Sell' on RailTel with a revised target of Rs 270 from Rs 280 earlier.

Stock market today: Indian frontline indices ended Thursday’s trading session (May 8) in the red, as escalating tensions between India and Pakistan weighed on investor sentiment. The Indian ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Revenue fell 9.2% YoY to $1.70B but topped the $1.67 billion estimate. Adjusted EPS surged to $1.06 vs. $0.65 expected. Get prepared for the Fed’s next move—live with Matt Maley on Wednesday ...